Human papillomavirus: footprints in the population of western India

Thobias, Ashi R.; Patel, Kinjal; Bhatt, Supreet; Mehta, Kruti A.; Parekh, Chetana; Dave, Pariseema; Patel, Prabhudas S

doi:10.4178/epih.e2021013

Cited by 4 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A comparison of the prevalence studies on HPV in India in development of the HNC tumour is difficult, because of different methods used in HPV detection, type of specimen used and geographical location of the study. Indian studies have reported varying HPV prevalence; these differences may be due to different detecting methodologies or demographics [ 10 – 13 ]. Our study shows a high prevalence of HPV16 for all sub-sites of HNC.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of human papillomavirus types in head and neck cancer sub-sites in the Indian population

Gholap¹,

Mhatre²,

Chaturvedi³

et al. 2022

ecancer

View full text Add to dashboard Cite

Although a subset of head and neck cancers (HNC) has been associated worldwide with mucosal high-risk human papillomaviruses (HPV), information on the prevalence of HPVpositive HNC in India is limited. In this study, we examined the prevalence of 21 subtypes of HPV in sub-sites of HNC (n = 175) in the western region of India. Type-specific multiplex genotyping assay was conducted at the Centre for Cancer Epidemiology, Tata Memorial Centre, to determine the prevalence of HPV subtypes. The HPV prevalence was observed to be 28.43%, 41.67%, 38.89% and 15.79% in the oral cavity, oropharynx, hypopharynx and larynx tumour tissues, respectively. The HPV 16 genotype was most common in all HNC tumour tissues (30.29%), followed by HPV 58 (0.57%).

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence of human papillomavirus types in head and neck cancer sub-sites in the Indian population

Gholap¹,

Mhatre²,

Chaturvedi³

et al. 2022

ecancer

View full text Add to dashboard Cite

show abstract

“…A global study in 2017 attributed 22.0% (95% (confidence interval) CI: 5.0-44.0) of oropharyngeal cancer incidence in India to HPV infection [4]. However, recent studies among Indian population reported wide variations of HPV prevalence among oropharyngeal cancer cases ranging between 0.0% in south India and 44.4% in north, followed by west (26.7%) with HPV 16 and 58 as the predominant genotypes [28][29][30][31][32][33]. Reported variations in HPV prevalence among cancer cases in India are due to different detection methods, population, geographic locations and sample size.…”

Section: Discussionmentioning

confidence: 99%

Epidemiology of human papillomavirus related cancers in India: findings from the National Cancer Registry Programme

Ramamoorthy¹,

Sathishkumar²,

Das³

et al. 2022

ecancer

View full text Add to dashboard Cite

Human papillomavirus (HPV) causes more than one-fourth of infection related cancers globally. The present study summarises the epidemiology of HPV related cancers in India, with a special focus on cervical and oropharyngeal cancer, utilising the National Cancer Registry Programme (NCRP) data. The data on HPV related cancer incidence and treatment were extracted from 28 population-based and 96 hospital-based cancer registries under the NCRP network. Incidence was presented as rates, clinical extent of disease and treatment provided as percentages. Joinpoint regression analysis was performed to calculate annual percent change in age adjusted incidence rates (AARs) over time. Incidence of HPV related cancers for 2025 was projected. Among all cancers, 7.5% were HPV related cancers. Cervical cancer (87.6%) and oropharyngeal cancer (63.2%) were the most common HPV related cancers in India among females and males, respectively. Cervical cancer was highest in Papumpare district (AAR: 27.7 per 100,000) and oropharyngeal cancer among males in East Khasi Hills district Population Based Cancer Registry (AAR: 11.4 per 100,000). In most PBCRS, cervical cancer incidence rate decreased significantly over the period of time. The majority of these cancers presented at locoregional spread stage of the disease and were treated with chemoradiation. The projected incidence of HPV related cancers is expected to increase to 121,302 by 2025. Implementation of effective prevention and control strategies like HPV vaccination and scaling up of screening could reduce the burden of HPV related cancers. Evidence from NCRP serves as the baseline to monitor the impact of HPV related policies and programmes in improving the outcome and prognosis.

show abstract

“…Table 1 summarizes the characteristics of the included studies. These studies vary in design, including prospective observational, [22,23] cohort, [24] and cross-sectional studies. [25][26][27][28][29][30][31][32][33][34][35][36][37][38] These studies encompass a wide range of Indian states and zones, from the southern regions of Tamil Nadu, Hyderabad, and Kerala [23,31,34] to the northern states like Uttar Pradesh, [37] and from the eastern state of Assam [27] to the central and western states such as Maharashtra, Bhopal, and Gujarat.…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Prevalence of human papilloma virus among cervical cancer patients in India: A systematic review and meta-analysis

Satapathy,

Khatib,

Neyazi

et al. 2024

Medicine

View full text Add to dashboard Cite

Background: Cervical cancer, predominantly caused by the human papillomavirus (HPV), is a major health challenge in India, with high morbidity and mortality rates. Given India’s vast geographic and socio-economic diversity, understanding regional variations in HPV prevalence is crucial for developing targeted and effective public health interventions. This systematic review and meta-analysis were conducted to elucidate the prevalence of HPV among cervical cancer patients in India. Methods: A literature search was executed across PubMed, EMBASE, and Web of Science up to December 07, 2023. Observational studies reporting HPV prevalence among cervical cancer patients in India are included. A Modified Newcastle-Ottawa scale was used for quality assessment. A random-effects meta-analysis was used to determine pooled HPV prevalence, and heterogeneity was evaluated using the I² statistic. Subgroup and sensitivity analyses were performed to assess result stability and investigate heterogeneity sources. All statistical analyses were performed using R software version 4.3. Results: The meta-analysis included 17 studies with a total of 2529 cervical cancer cases, of which 1977 were HPV-positive. The pooled HPV prevalence was 85% (95% CI: 71–92%), with substantial heterogeneity (I² = 94%). Subgroup analysis by geographic zones showed notable differences: South (88%, 95% CI: 76–95%), North (73%, 95% CI: 1–100%), East (99%, 95% CI: 1–100%), Central (71%, 95% CI: 54–84%), and West (77%, 95% CI: 0–100%). Sensitivity analysis demonstrated the consistency of the results, and a reanalysis, excluding influential studies, yielded a prevalence of 82% (95% CI: 67–91%). Conclusion: Our analysis reveals a high prevalence of HPV in cervical cancer patients in India, with significant regional variations. The observed heterogeneity highlights the complexity of HPV epidemiology in India and necessitates further research to explore underlying causes and regional characteristics. Future studies should aim to expand geographic representation and deepen understanding of the factors contributing to the variability in HPV prevalence.

show abstract

Human papillomavirus: footprints in the population of western India

Cited by 4 publications

References 27 publications

Prevalence of human papillomavirus types in head and neck cancer sub-sites in the Indian population

Prevalence of human papillomavirus types in head and neck cancer sub-sites in the Indian population

Epidemiology of human papillomavirus related cancers in India: findings from the National Cancer Registry Programme

Prevalence of human papilloma virus among cervical cancer patients in India: A systematic review and meta-analysis

Contact Info

Product

Resources

About